Skip to main content
SpringerLink
Log in
Book cover

Intracellular Delivery III

Market Entry Barriers of Nanomedicines

  • Book
  • © 2016

Overview

Editors:
  1. Aleš Prokop

    1. Biomolecular and Chemical Engineering, Vanderbilt University Biomolecular and Chemical Engineering, Nashville, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Volkmar Weissig

    1. Pharmaceutical Sciences, Midwestern University Pharmaceutical Sciences, GLENDALE, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • Comprehensive set of reviews dealing with cellular (tissue) and intracellular targeting of nanovehicles
  • Covers classical and computational means of nanovehicle targeting
  • Delivers important application areas in medicine
  • Written by world experts in this field

Part of the book series: Fundamental Biomedical Technologies (FBMT)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (17 chapters)

  1. Front Matter

    Pages i-xiii
    Download chapter PDF

  2. Introductory Chapters

    1. Front Matter

      Pages 1-1
      Download chapter PDF

    2. Overview of Present Problems Facing Commercialization of Nanomedicines

      • Aleš Prokop, Volkmar Weissig
      Pages 3-36

    3. Precision Drugs and Cell-Specific Drug Delivery

      • Karel Petrak
      Pages 37-46

  4. How to Extend the Circulation Time of Nanovehicles

    1. Front Matter

      Pages 123-123
      Download chapter PDF

    2. A New Approach to Decrease the RES Uptake of Nanodrugs by Pre-administration with Intralipid® Resulting in a Reduction of Toxic Side Effects

      • Li Liu, Chien Ho
      Pages 125-146

  5. Differences Between In Vivo Status in Men and Mice

    1. Front Matter

      Pages 147-147
      Download chapter PDF

    2. Authentic Vascular and Stromal Structure in Animal Disease Model for Nanomedicine

      • Hiroshi Nishihara, Mitsunobu R. Kano
      Pages 149-160

  6. Cell-Specific Targeting

    1. Front Matter

      Pages 161-161
      Download chapter PDF

    2. Ligand-targeted Particulate Nanomedicines Undergoing Clinical Evaluation: Current Status

      • Roy van der Meel, Laurens J. C. Vehmeijer, Robbert Jan Kok, Gert Storm, Ethlinn V. B. van Gaal
      Pages 163-200

    3. Anti-angiogenic Therapy by Targeting the Tumor Vasculature with Liposomes

      • Yu Sakurai, Hideyoshi Harashima
      Pages 201-228

    4. Accessing Mitochondrial Targets Using NanoCargos

      • Ru Wen, Afoma C. Umeano, Shanta Dhar
      Pages 229-254

    5. Redox-Responsive Nano-Delivery Systems for Cancer Therapy

      • Amit Singh, Thanh-Huyen Tran, Mansoor M. Amiji
      Pages 255-269

  7. Improved Imaging

    1. Front Matter

      Pages 271-271
      Download chapter PDF

    2. Nano-emulsions for Drug Delivery and Biomedical Imaging

      • Nicolas Anton, François Hallouard, Mohamed F. Attia, Thierry F. Vandamme
      Pages 273-300

    3. The Tumor Microenvironment in Nanoparticle Delivery and the Role of Imaging to Navigate Roadblocks and Pathways

      • Dmitri Artemov, Zaver M. Bhujwalla
      Pages 301-322

    4. Microscopic Mass Spectrometry for the Precise Design of Drug Delivery Systems

      • Yasuhiro Matsumura, Masahiro Yasunaga
      Pages 323-337
Back to top

Keywords

About this book

A critical review is attempted to assess the status of nanomedicine entry onto the market. The emergence of new potential therapeutic entities such as DNA and RNA fragments requires that these new “drugs” will need to be delivered in a cell-and organelle-specific manner. Although efforts have been made over the last 50 years or so to develop such delivery technology, no effective and above all clinically approved protocol for cell-specific drug delivery in humans exists as yet. Various particles, macromolecules, liposomes and most recently “nanomaterials” have been said to “show promise” but none of these promises have so far been “reduced” to human clinical practice. 
The focus of this volume is on cancer indication since the majority of published research relates to this application; within that, we focus on solid tumors (solid malignancies). Our aim is critically to evaluate whether nanomaterials, both non-targeted and targeted to specific cells, could be of therapeutic benefit in clinical practice. The emphasis of this volume will be on pharmacokinetics (PK) and pharmacodynamics (PD) in animal and human studies. 
Apart from the case of exquisitely specific antibody-based drugs, the development of target-specific drug–carrier delivery systems has not yet been broadly successful at the clinical level. It can be argued that drugs generated using the conventional means of drug development (i.e., relying on facile biodistribution and activity after (preferably) oral administration) are not suitable for a target-specific delivery and would not benefit from such delivery even when a seemingly perfect delivery system is available. Therefore, successful development of site-selective drug delivery systems will need to include not only the development of suitable carriers, but also the development of drug entities that meet the required PK/PD profile. 


Editors and Affiliations

  • Biomolecular and Chemical Engineering, Vanderbilt University Biomolecular and Chemical Engineering, Nashville, USA

    Aleš Prokop

  • Pharmaceutical Sciences, Midwestern University Pharmaceutical Sciences, GLENDALE, USA

    Volkmar Weissig

Bibliographic Information

  • Book Title: Intracellular Delivery III

  • Book Subtitle: Market Entry Barriers of Nanomedicines

  • Editors: Aleš Prokop, Volkmar Weissig

  • Series Title: Fundamental Biomedical Technologies

  • DOI: https://doi.org/10.1007/978-3-319-43525-1

  • Publisher: Springer Cham

  • eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)

  • Copyright Information: Springer International Publishing Switzerland 2016

  • Hardcover ISBN: 978-3-319-43523-7Published: 23 December 2016

  • Softcover ISBN: 978-3-319-82846-6Published: 12 July 2018

  • eBook ISBN: 978-3-319-43525-1Published: 31 October 2016

  • Series ISSN: 1559-7083

  • Series E-ISSN: 2626-8655

  • Edition Number: 1

  • Number of Pages: XIII, 453

  • Number of Illustrations: 16 b/w illustrations, 65 illustrations in colour

  • Topics: Biomedicine general, Nanotechnology

Publish with us

Policies and ethics

Back to top

Search

Navigation